Description
A potent inhibitor of DYRKs and CLKs. Interacts also with GSK-3α/β, CK2 and PIM1. Interacts with the complex IKfyve/Vac14/Fig4. Modulates alternative splicing of pre-mRNA in various cellular systems. Neuroprotective against APP-induced cell death. Useful to study and modulate pre-RNA splicing. Potential compound for Alzheimer's disease and diseases involving abnormal pre-mRNA splicing. Potential compound to study Down syndrome (inhibition of DYRK1A). Neuroprotective against glutamate-induced cell death.
Leucettine L41 is a potent inhibitor of DYRKs and CLKs. Interacts also with GSK-3α/β, CK2 and PIM1. Interacts with the complex IKfyve/Vac14/Fig4. Modulates alternative splicing of pre-mRNA in various cellular systems. Neuroprotective against APP-induced cell death. Useful to study and modulate pre-RNA splicing. Potential compound for Alzheimer's disease and diseases involving abnormal pre-mRNA splicing.
2617 | Leucettine L41 DataSheet
Alternate Name/Synonyms: (5Z)-5-(1,3-Benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4H-imidazol-4one
Appearance: Beige solid
Formulation: N/A
CAS Number: 1112978-84-3
Structure Available?: Y
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₇H₁₃N₃O₃
Molecular Weight: 307.3
Cell-Permeable?: Yes
Purity: >98% by NMR
Solubilities: DMSO or EtOH
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent inhibitor of DYRKs and CLKs
MDL Number: N/A
PubChem CID: N/A
SMILES: O=C1NC(NC2=CC=CC=C2)=N/C1=C\C3=CC=C(OCO4)C4=C3
InChi: InChI=1S/C17H13N3O3/c21-16-13(8-11-6-7-14-15(9-11)23-10-22-14)19-17(20-16)18-12-4-2-1-3-5-12/h1-9H,10H2,(H2,18,19,20,21)/b13-8-
InChi Key: PGPHHJBZEGSUNE-JYRVWZFOSA-N
Additional Information
Storage Condition: |
-20 ̊C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |